The Instituto Valenciano de Infertilidad (IVI) and the Reproductive Medicine Associates of New Jersey (RMANJ) have announced their merger after one year of negotiations, creating a new company to be known as IVI-RMA Global, headquartered in Valencia. This move provides the Spanish company with an entry into the United States and ensures its consolidation as the largest assisted reproduction group in the world, with a predicted annual turnover of 300 million euros.
Doctors Antonio Pellicer and José Remohí created the IVI in 1990, and the company soon became a leader at the scientific and commercial level in the field of reproductive endocrinology, in which it has also received numerous awards and patents. Before the merger, it was present in 60 clinics in 11 countries and attended over 60,000 patients.
Its new traveling companion, RMANJ, was founded in 1999, and has since become one of the biggest names in in vitro fertilization in the United States, with an almost 70% increase in patients in the last five years. With ten clinics in the United States, the first goal of the new IVI-RMA Global will be to continue expanding in that country.
IVI's shareholders will retain a majority stake in the new group, estimated at 70%, and the rest be held by RMNAJ. The new company will have a total of around 2,400 employees, including over 200 doctors and 300 researchers.
According to both parties, its vocation is “to continue being leaders in the fields of research and scientific knowledge. The ultimate aim of this union is to share the best practices and the latest technologies in every phase of the various treatments offered, always for the benefit of our patients”.
Professor Richard Scott, one of the chairmen of RMNAJ, says: “As a single global entity, there are no geographical or any other kind of limits to our commitment to provide fertility solutions based on scientific evidence in order to offer the best chance of success in the shortest time possible. Along with IVI, we can seek new markets and bring hope to all those patients who have problems with infertility”.
Antonio Pellicer adds: “I have always pursued the goal of introducing my company in the USA and today I am pleased to announce that we have made it. The key to achieve this step was to go hand-in-hand with RMANJ. We share much the same medical-scientific and business values and interests. This merger will allow us to take full advantage of the expertise, experience and distinguishing elements of both companies for the benefit of our patients and employees”.
For his part, José Remohí says: “This union will allow us to enhance our field of investigation, the fundamental pillar of IVI since its inception which has enabled us to achieve high rates of success, a fact that our patients value when choosing our services”.
Last updated: 17|03|2017